Sanofi site to produce asthma inhaler tech

SkyePharma will spend £5 million ($7.8 million) to help build a facility in the U.K. that will manufacture the new Flutiform asthma inhaler tech for Sanofi ($SNY). The treatment recently gained European regulatory approval, according to the Manchester Evening News. Production will take place at Sanofi's Holmes Chapel facility beginning in September. About 260 people work there now, and at least 40 will be initially involved in the production, testing and distribution of the inhaler. Employment will double, however, in subsequent years as demand increases, according to company officials. Story

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Babson Diagnostics has closed its series A funding round with a total of $13.7 million and named a new CEO.